证券日报网讯 2月12日，中牧股份在互动平台回答投资者提问时表示，公司部分产品生产技术符合合成 生物技术特征。 （文章来源：证券日报） ...

（编辑 楚丽君） 证券日报网讯 2月12日，中牧股份在互动平台回答投资者提问时表示，公司生产经营平稳有序，公司产 品市场占有率仍保持较大韧性和活力。2025年，公司积极应对多重压力，及时优化营销结构，深挖客户 需求，积极开发新产品、拓展新业务；同时公司也进一步加强对日常运营的统筹管理，努力推进公司整 体的降本增效。具体财务数据请以公司后续披露的经审计年报为准。 ...

Core Viewpoint - The company has decided to suspend the research and application of the African Swine Fever freeze-dried inactivated vaccine due to significant uncertainties and challenges in the project, which will also lead to the recognition of goodwill impairment [14][19][21]. Group 1: Suspension of Vaccine Development - The board of directors unanimously approved the suspension of the African Swine Fever vaccine development project [14][20]. - The decision was made after recognizing the high technical difficulty and long regulatory approval cycles associated with the vaccine development [19][21]. - The suspension is not expected to have a significant adverse impact on the company's existing business operations [21]. Group 2: Goodwill Impairment - The company plans to recognize a goodwill impairment of approximately 17,499.47 million yuan due to the suspension of the vaccine project [30]. - This impairment is expected to reduce the net profit attributable to shareholders by about 14,981.30 million yuan for the fiscal year 2025 [30]. - The board believes that this impairment aligns with accounting standards and reflects the company's asset status more accurately [30]. Group 3: Financing Lease Business - The company approved a financing lease agreement for its subsidiary, aiming to optimize financing structure and enhance asset liquidity [33][49]. - The total financing amount is expected to be up to 14,100 million yuan, with a lease term of 30 months [33][49]. - The company will provide a guarantee for the financing lease based on its ownership percentage in the subsidiary [34][49]. Group 4: Change of Fundraising Purpose - The company has decided to change the use of unutilized fundraising from the "Animal Vaccine Production Base Construction Project" to two new projects: "Energy System and Fermentation System Optimization Project" and "3,500 tons/year Powder and Granule Automated Closed Production Line Project" [52][55]. - The total amount to be reallocated is 9,254.83 million yuan, which is approximately 11.54% of the actual net fundraising amount [53][55]. - This change is aimed at improving the efficiency of fundraising use and aligning with the company's operational needs [52][55].

Group 1 - The core viewpoint of the news is that Jinhe Biology's stock has seen a significant increase of 5.16%, reaching 6.72 CNY per share, with a trading volume of 205 million CNY and a turnover rate of 4.22%, resulting in a total market capitalization of 5.185 billion CNY [1] - Jinhe Biology, established on March 14, 1990, and listed on July 13, 2012, is located in Inner Mongolia and specializes in the production, sales, research, and services of animal health products [1] - The company's main business revenue composition includes: veterinary chemical drugs 61.83%, starch and related products 19.76%, veterinary vaccines 11.12%, environmental services 4.97%, others 2.15%, and drug feed additives 0.18% [1] Group 2 - From the perspective of major circulating shareholders, Guotai Fund's ETF, Guotai Zhongzheng Animal Husbandry ETF (159865), increased its holdings by 4.3964 million shares, totaling 12.0555 million shares, which accounts for 1.61% of the circulating shares [2] - The Guotai Zhongzheng Animal Husbandry ETF has a current scale of 5.949 billion CNY, with a year-to-date loss of 0.41%, ranking 5172 out of 5580 in its category; over the past year, it has achieved a return of 15.98%, ranking 3639 out of 4271; since its inception, it has a loss of 37.07% [2] Group 3 - The fund manager of Guotai Zhongzheng Animal Husbandry ETF is Liang Xing, who has a cumulative tenure of 9 years and 235 days, with the fund's total asset scale at 29.35 billion CNY [3] - During Liang Xing's tenure, the best fund return was 1112.34%, while the worst return was -54.39% [3]

Core Viewpoint - The article highlights the recognition of Zhejiang Haizheng Animal Health Products Co., Ltd. as the leading player in the Chinese pet medicine market, with its product Hailuwang being the top-selling dog deworming product nationwide [1][15][16]. Company Overview - Zhejiang Haizheng Animal Health Products Co., Ltd. is a subsidiary of Zhejiang Haizheng Pharmaceutical Co., Ltd. (stock code: 600267), which has invested 800 million RMB to build an international animal health enterprise [4]. - The company operates two major production bases in Fuyang and Kunming, producing a wide range of products including injections, tablets, and various vaccines [5]. Product Details - Hailuwang is a specialized dog deworming product available in multiple packaging specifications, primarily containing Milbemycin Oxime and Praziquantel, effective against various common parasites [7]. - The product is designed for dogs over 2 weeks old and weighing more than 0.5 kg, featuring a palatable beef flavor [7]. Competitive Advantages - Haizheng Animal Health's rapid growth is attributed to its parent company's pharmaceutical expertise and stringent quality control across the entire production chain [9]. - The company emphasizes six core competitive advantages: 1. Pure raw materials with low impurity levels [9]. 2. Lean R&D leveraging the parent company's strong capabilities [10]. 3. International production lines adhering to high-quality standards [10]. 4. Rigorous quality control throughout the production process [10]. 5. Multiple international certifications including GMP and ISO [10]. 6. Commitment to high-quality, stable products that align with green principles [10]. Industry Development - The Chinese pet medicine industry has evolved from reliance on imported products to a phase of independent innovation, with significant growth in domestic brands since 2010 [11][12]. - The market for dog deworming products has transitioned from basic availability to a more sophisticated supply, reflecting the rise of domestic brands and a shift towards preventive health care [13]. Market Position - Haizheng Animal Health's sales are projected to reach approximately 500 million RMB from 2024 to October 2025, confirming its position as the top-selling domestic pet medicine brand [15]. - The Hailuwang product has achieved over 6.03 million units sold from 2020 to October 2025, establishing it as the leading dog deworming product in the domestic market [16]. Industry Ecosystem - The production and distribution systems for domestic pet medicines are becoming increasingly sophisticated, with companies enhancing quality control and supply chain management [14]. - The industry is moving towards a more regulated and diversified development model, supported by ongoing improvements in regulatory frameworks and digital upgrades in pet healthcare [14].

Financial Data and Key Metrics Changes - The company reported product sales for Q4 2025 at $7.6 million, a decrease of 1.6% compared to Q4 2024, primarily due to a previous backorder situation that inflated sales in the prior year [12][13] - Domestic sales grew by 8.7% year-over-year to $7 million, while international sales declined by 52.6% due to order timing in Canada [13][14] - Full-year product sales for 2025 totaled $27.6 million, reflecting a 4.3% increase compared to 2024 [14] Business Line Data and Key Metrics Changes - The First Defense product line saw significant growth, with Tri-Shield experiencing a 41.3% increase in Q4 2025 compared to Q4 2024, indicating a shift from Dual-Force products [5][14] - The company is focusing on increasing manufacturing output for First Defense, achieving over a 15% increase in lyophilization output in 2025, with expectations for similar growth in 2026 [9][18] Market Data and Key Metrics Changes - The newborn calf market has evolved, with calf values increasing significantly, leading to a greater economic emphasis on early-life calf health and survival [8] - The total addressable market for scour protection is estimated at approximately $900 million worldwide, indicating substantial growth potential for First Defense products [8] Company Strategy and Development Direction - The company is shifting its strategic focus to First Defense, pausing investments in Re-Tain due to an Incomplete Letter from the FDA, which has delayed the product's approval process [6][7] - The strategy includes expanding the sales team by 50% and creating two new U.S. sales territories to drive growth in First Defense [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of First Defense, citing the need for increased focus and execution to capitalize on market opportunities [6][9] - The company plans to complete investigational studies for Re-Tain to prepare for potential partnerships, emphasizing that manufacturing in-house is not the best use of resources [11][41] Other Important Information - A non-cash impairment write-down of approximately $2.9 million is expected due to the shift in strategy regarding Re-Tain [15] - An estimated write-down of $600,000 for inventory deemed unsuitable for requirements has been planned [16] Q&A Session Summary Question: Impact of regional pathogens on foreign sales development - Management acknowledged the complexity of international sales and the need for experienced personnel to navigate product requirements and market strategies [21][22] Question: Explanation for contract manufacturer's failure to comply with FDA requirements - Management declined to provide details but confirmed that the Incomplete Letter was solely due to issues with the contract manufacturer [24][25] Question: Timeline for securing a strategic partner for Re-Tain - Management expressed confidence in the product's capabilities and indicated that they would seek partners after completing investigational studies in 2026 [28][41] Question: Clarity on the self-imposed milk discard period for Re-Tain - Management clarified that the discard period is necessary to prevent impact on cheese manufacturing processes, although it is less than competitors [46][48] Question: Explanation for exceeding sales expectations - Management attributed the sales exceeding expectations to effective management practices and a strong commercial team, despite complexities from previous backorder situations [52][55]

Group 1 - The company announced that it will provide a guarantee for its wholly-owned subsidiary, Inner Mongolia Jinhai Environmental Technology Co., Ltd., to secure a loan of up to 100 million RMB from China Construction Bank for a wastewater treatment plant expansion project [1] - The loan is intended for a five-year term with an interest rate based on the current LPR rate, specifically for the project aimed at enhancing wastewater treatment capacity and water resource recycling [1] - As of the announcement date, the total external guarantee balance for the company and its subsidiaries is approximately 463 million RMB, which includes the new guarantee and represents 20.61% of the audited net assets attributable to the parent company for 2024 [1] Group 2 - The new guarantee amount of 100 million RMB will account for 4.45% of the audited net assets attributable to the parent company for 2024 [1] - The guarantee requires approval from the company's shareholders through a special resolution and does not involve related party transactions or require approval from relevant authorities [1]

Core Insights - The article highlights the recent approval of a feed additive product, red yeast, by Jinhe Biological, which is expected to enhance the company's product structure and market competitiveness [2][3]. Product Development - Jinhe Biological has received the product approval number for red yeast, which is a feed additive, with the approval date set for September 15, 2025 [3]. - The approval of red yeast is anticipated to positively impact the company's operational performance and market competitiveness [3]. Key Ingredient and Benefits - Red yeast produces astaxanthin during fermentation, which is a powerful natural antioxidant with applications in aquaculture, feed industry, health care, and cosmetics [3]. - Astaxanthin is recognized for its superior antioxidant capacity compared to common antioxidants [3]. Production Methods - The primary sources of astaxanthin include natural extraction, chemical synthesis, and microbial fermentation, with the latter being favored for its safety, stability, and practicality [4]. - Red yeast is noted for its rapid growth cycle, short fermentation period, and ability to utilize various carbon sources, making it commercially valuable [4]. Company Strategy - Jinhe Biological has established a project with an annual production capacity of 3,000 tons of astaxanthin, indicating a strategic focus on research and innovation in synthetic biology applications [5].

Core Viewpoint - The company indicated that fluctuations in raw material prices are just one of the factors affecting its performance, and these price changes are not predictable. A detailed disclosure of the fourth-quarter operating conditions will be provided in the 2025 annual report [1] Group 1 - The company responded to investor inquiries on November 5 regarding the impact of raw material prices on its performance [1] - The company emphasized that the changes in raw material prices do not have predictive qualities [1] - A comprehensive report on the fourth-quarter performance will be included in the 2025 annual report [1]

Core Viewpoint - The company is actively implementing a market value management system to enhance its market value management efforts [1] Group 1 - The company responded to investor inquiries on an interactive platform regarding its market value management initiatives [1] - The company is aligning its market value management strategy with relevant requirements and its actual situation [1]